Summary
For Year 2026-27, Beta Drugs reports the following shareholding: Total Promoters at 64.63%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 1.16%, Domestic Institutional Investors at 2.14%, and Retail at 32.07%. This breakdown provides a quick snapshot of ownership distribution for Beta Drugs in 2026-27.
Beta Drugs FAQs
As of 04-2026, the promoter shareholding in Beta Drugs stands at 64.63% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Beta Drugs is 1.16% and 2.14% respectively.
The retail shareholding of the Beta Drugs is 32.07%.
Changes in shareholding patterns of Beta Drugs can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Beta Drugs are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
